LOSS OF EFFECT OF ASPIRIN

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 假设：1)阿司匹林(ASA)对体外诱导的血小板聚集的抑制作用随时间和剂量的变化而变化。(2)血栓烷和前列环素的产生被ASA以剂量依赖的方式抑制，一旦出现最大的抑制，则随着时间的推移保持相对恒定。(3)阿司匹林可显著抑制血小板诱导聚集过程中的颗粒分泌，但这种作用在高剂量慢性给药过程中不会持续。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Hypotheses: 1)Inhibition by aspirin (ASA) of ex vivo induced platelet aggregation varies in a predictable time and dose dependent manner. (2)Thromboxane and Prostacyclin production is inhibited by ASA in a dose dependent manner and remains relatively constant over time once maximal inhibition has occurred. (3) Granule secretion by platelets during induced aggregation is inhibited by aspirin acutely but this effect does not persist during chronic administration at high